A biotech company developing groundbreaking therapies using gene editing and personalized medicine approaches.
Challenge:
The biotech company was engaged in the development of gene-editing tools and treatments for rare diseases. They needed to push the boundaries of scientific research and technology to create effective therapies and ensure safety and efficacy.
R&D Activities
Gene Editing Research:
The company was heavily involved in CRISPR-based research to target genetic diseases at the molecular level.
Biomanufacturing Processes:
They worked on scaling up production methods to produce gene-edited cells and biologics for clinical trials.
Drug Development:
The company conducted various trials to test the efficacy of its gene-editing therapies and improve manufacturing processes.
Eligibility for R&D Tax Credit:
The gene-editing research, testing, and development of new biomanufacturing processes were eligible for the R&D Tax Credit. The labor of scientists and engineers involved in the research, as well as the materials and equipment used in testing, could be claimed under the credit.
Result:
The biotech company received substantial tax relief, enabling them to reinvest in further clinical development, regulatory approval processes, and manufacturing capabilities to bring their therapies to market.
Let's Get Started
Schedulea Free Consultation
Ready to amplify your client offerings and discover unclaimed tax savings? Contact us today to discuss a partnership or
schedule a no-obligation consultation. Let WeIncentivize be your partner in empowering financial success for your
clients.
